iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/2071558/
Fluoxetine in the treatment of late luteal phase dysphoric disorder - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1991 Jul;52(7):290-3.

Fluoxetine in the treatment of late luteal phase dysphoric disorder

A B Stone  1 , T B Pearlstein, W A Brown
Affiliations
  • PMID: 2071558
Clinical Trial

Fluoxetine in the treatment of late luteal phase dysphoric disorder

A B Stone et al. J Clin Psychiatry. 1991 Jul.

Abstract

Background: Despite many associations between late luteal phase dysphoric disorder (LLPDD) and major depression, there have been no placebo-controlled trials of an antidepressant in this disorder.

Method: The authors conducted a double-blind, randomized, placebo-controlled trial of fluoxetine in the treatment of LLPDD. The diagnosis of LLPDD was based on daily, prospective self-rating forms that subjects completed over two menstrual cycles. Subjects with other psychiatric disorders, determined by the Schedule for Affective Disorders and Schizophrenia interview, were excluded from the study. Women who continued to meet criteria for LLPDD after a single-blind trial of placebo were randomly assigned to treatment for two menstrual cycles with either fluoxetine 20 mg/day (N = 10) or placebo (N = 10).

Results: Nine of the 10 subjects receiving fluoxetine responded to treatment, whereas only 2 of the 10 receiving placebo did (p less than .0003). Symptoms decreased significantly in all 10 LLPDD diagnostic categories in the fluoxetine-treated group. All subjects taking fluoxetine elected to continue with this treatment after completion of the study.

Conclusions: These results suggest that fluoxetine is an effective and well-tolerated treatment for LLPDD.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

LinkOut - more resources